Filings & corporate actions
53 results filed
CSVNext results · Q2 FY27
Expected 3 Nov 2026 – 13 Nov 2026
Estimate: filed 34–44 days after quarter end, last 5 times
Dividend
₹4.00 per share · last 18 Sept 2026
2026
- 18 SeptdividendDividend · ₹4.00 per share+5.9%
- 12 AugresultsResults · Q1 FY27 · consolidated and standalone+1.1%NSE
- 21 JulshareholdingShareholding · 30 Jun 2026-1.6%NSE
- 29 MaydividendDividend · ₹4.00 per share+0.1%
- 14 MayresultsResults · Q4 FY26 · consolidated and standalone-1.2%NSE
- 21 AprshareholdingShareholding · 31 Mar 2026-0.3%NSE
- 5 FebresultsResults · Q3 FY26 · consolidated and standalone-4.1%NSE
- 19 JanshareholdingShareholding · 31 Dec 2025-0.8%NSE
Reaction to results · all yearsrose on day 0 in 22 of 49 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 12 Aug 2026 | +1.1% | +2.3% | +13.1% | 1.1× |
| Q4 FY26 | 14 May 2026 | -1.2% | +0.2% | +16.8% | 2.1× |
| Q3 FY26 | 5 Feb 2026 | -4.1% | -9.1% | -12.3% | 2.3× |
| Q2 FY26 | 5 Nov 2025 | +0.5% | -2.9% | -1.0% | 3.4× |
| Q1 FY26 | 7 Aug 2025 | +2.6% | +4.5% | +7.1% | 4.2× |
| Q4 FY25 | 15 May 2025 | +0.5% | +9.6% | +7.0% | 0.7× |
| Q3 FY25 | 7 Feb 2025 | -4.4% | -10.4% | -13.8% | 1.2× |
| Q2 FY25 | 8 Nov 2024 | -5.2% | -6.3% | +12.4% | 1.1× |
| Q1 FY25 | 7 Aug 2024 | -6.3% | +0.3% | +26.8% | 1.8× |
| Q4 FY24 | 17 May 2024 | -1.6% | -4.4% | +1.3% | 1.8× |
| Q3 FY24 | 9 Feb 2024 | -0.8% | +9.2% | -4.9% | 1.9× |
| Q2 FY24 | 10 Nov 2023 | +8.4% | +16.3% | +8.7% | 17.2× |
| Q1 FY24 | 8 Aug 2023 | +11.1% | +18.5% | +22.0% | 11.4× |
| Q4 FY23 | 27 May 2023 | -0.1% | +3.7% | +8.3% | 2.2× |
| Q3 FY23 | 11 Feb 2023 | -1.2% | -4.3% | -10.6% | 2.9× |
| Q2 FY23 | 13 Nov 2022 | +6.0% | +0.6% | -1.1% | 8.7× |
| Q1 FY23 | 5 Aug 2022 | -0.8% | -2.0% | -4.1% | 0.4× |
| Q4 FY22 | 13 May 2022 | +6.7% | +17.1% | +15.0% | 2.5× |
| Q3 FY22 | 4 Feb 2022 | -2.9% | -5.7% | -15.1% | 0.7× |
| Q2 FY22 | 3 Nov 2021 | +0.9% | +2.8% | -2.3% | 0.8× |
| Q1 FY22 | 5 Aug 2021 | -2.2% | -6.9% | -8.2% | 0.3× |
| Q4 FY21 | 7 May 2021 | +3.1% | +12.4% | +6.6% | 2.7× |
| Q3 FY21 | 4 Feb 2021 | -3.1% | -2.8% | -4.6% | 1.5× |
| Q2 FY21 | 1 Dec 2020 | -1.0% | +3.6% | +2.7% | 0.6× |
| Q1 FY21 | 11 Aug 2020 | -6.3% | -4.8% | -7.9% | 1.0× |
| Q4 FY20 | 19 Jun 2020 | +1.0% | -11.6% | +8.1% | 1.0× |
| Q3 FY20 | 7 Feb 2020 | +4.9% | -3.0% | -17.0% | 3.1× |
| Q2 FY20 | 31 Oct 2019 | -3.1% | -12.7% | -26.2% | 1.6× |
| Q1 FY20 | 13 Aug 2019 | +4.2% | -3.1% | +4.3% | 3.0× |
| Q4 FY19 | 23 May 2019 | -3.8% | +4.0% | +1.9% | 1.4× |
| Q3 FY19 | 19 Feb 2019 | +2.0% | +19.8% | +25.2% | 0.9× |
| Q2 FY19 | 20 Nov 2018 | +0.8% | -1.6% | -6.1% | 0.5× |
| Q1 FY19 | 24 Aug 2018 | +0.2% | +8.1% | +5.5% | 0.2× |
| Q4 FY18 | 26 Jun 2018 | -1.4% | -5.5% | -3.3% | 0.7× |
| Q3 FY18 | 12 Mar 2018 | +0.3% | -4.4% | -0.4% | 0.6× |
| Q2 FY18 | 11 Nov 2017 | -3.5% | -1.1% | -4.2% | 1.8× |
| Q1 FY18 | 21 Aug 2017 | -2.2% | -3.3% | +7.8% | 0.5× |
| Q4 FY17 | 27 May 2017 | -3.3% | -2.9% | +2.0% | 0.3× |
| Q3 FY17 | 8 Feb 2017 | -1.9% | -10.0% | -11.4% | 0.5× |
| Q1 FY17 | 6 Dec 2016 | -0.5% | -1.9% | -4.4% | 0.7× |
| Q2 FY17 | 29 Nov 2016 | -0.8% | -2.5% | -8.1% | 0.3× |
| Q4 FY16 | 30 May 2016 | +1.6% | -2.8% | -1.4% | 1.2× |
| Q3 FY16 | 5 Feb 2016 | -4.1% | -16.6% | -13.8% | 1.3× |
| Q2 FY16 | 5 Nov 2015 | +2.5% | -1.0% | +4.2% | 3.9× |
| Q1 FY16 | 21 Aug 2015 | +7.8% | +1.4% | +10.6% | 8.0× |
| Q4 FY15 | 13 May 2015 | 0.0% | -3.8% | -6.8% | 0.3× |
| Q3 FY15 | 4 Feb 2015 | -10.0% | -5.2% | +20.9% | 0.5× |
| Q2 FY15 | 20 Nov 2014 | +1.6% | +5.5% | -2.1% | 0.5× |
| Q1 FY15 | 28 Aug 2014 | +0.9% | +7.3% | -10.2% | 1.3× |
| Average | -0.1% | -0.1% | +0.8% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY+19.6%
Profit YoY+18.8%
Interest cost YoY—
Revenue QoQ+1.7%
Profit QoQ+3.6%
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen2,611.00
Day range2,583.00 – 2,691.20
52-week range1,500.30 – 2,990.00
From 52w high-10.4%
RSI (14)48.9
ATR (14)113.54
Volume1.11L
Avg volume (20D)1.99L
Rel volume0.56×
Volatility (1Y)33.6%
Turnover₹29.7Cr
SMA 50 / 2002,637.97 / 2,123.03
Delivery percentage
Latest · 6 Oct 202641.7%
20-day avg35.5%
1-year avg46.0%
Percentile (own history)41st
Range5.8–84.2%
Sessions1,731
Over the last 20 sessions CAPLIPOINT settled 35.5% of its traded quantity, which is ordinary for an NSE equity. Its one-year average is 46.0%, so recent sessions are running 10.6 points lower than usual. The latest session ranks higher than 41% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +2.91% | -6.11% | -5.81% | +4.40% | +71.14% | +31.56% |
Valuation
CSVMarket cap₹20,369 Cr
P/E (TTM)30.0
EPS (TTM)89.20
Shares outstanding7.60Cr
Listed23 Jun 2014
Ownership
CSVPromoter70.57%
Promoter Δ QoQ0.00 pp
Public29.43%
FII5.75%
DII2.49%
Pledged0.00%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 534.0 | 542.8 | 600.2 | 610.4 |
| YoY chg | — | — | +19.4% | +19.6% |
| Net profit (₹ Cr) | 160.2 | 165.9 | 172.9 | 179.1 |
| YoY chg | — | — | +19.0% | +18.8% |
| Net margin | 30.0% | 30.6% | 28.8% | 29.3% |
| EPS | 20.25 | 21.51 | 22.31 | 23.21 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 70.57% · public 29.43%2021-092026-06
- Promoter
- Public and others
- Promoter
- 70.57%
- Public
- 29.43%
- Promoter change
- 0.00 pp
- Filed
- 21 Jul 2026
- FII
- 5.75%
- DII
- 2.49%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 410.1 | 435.5 | 453.2 | 459.0 | 483.1 | 493.0 | 502.5 | 510.2 | 534.0 | 542.8 | 600.2 | 610.4 | |
| Other income | 20.4 | 17.2 | 17.3 | 18.6 | 20.8 | 31.4 | 25.7 | 23.1 | 30.4 | 33.7 | 28.4 | 33.6 | |
| Total income | 430.5 | 452.7 | 470.5 | 477.5 | 503.9 | 524.3 | 528.2 | 533.4 | 564.4 | 576.5 | 628.5 | 643.9 | |
| Total expenses | 284.6 | 307.3 | 324.5 | 323.2 | 335.3 | 347.1 | 351.6 | 348.9 | 363.4 | 372.5 | 415.1 | 418.7 | |
| └ Finance costs | 0.2 | 0.2 | 0.2 | 0.1 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.2 | 0.4 | 0.2 | |
| └ Depreciation | 11.8 | 13.9 | 16.4 | 16.0 | 16.8 | 16.2 | 17.0 | 16.3 | 18.4 | 19.3 | 18.8 | 21.6 | |
| Profit before tax | 145.9 | 145.4 | 146.0 | 154.4 | 168.6 | 177.3 | 176.6 | 184.4 | 201.0 | 203.9 | 213.4 | 225.2 | |
| Tax expense | 29.9 | 25.6 | 24.8 | 29.5 | 37.7 | 37.2 | 31.4 | 33.7 | 40.8 | 38.0 | 40.6 | 46.1 | |
| Net profit | 116.1 | 119.8 | 121.2 | 124.9 | 130.8 | 140.1 | 145.3 | 150.8 | 160.2 | 165.9 | 172.9 | 179.1 | |
| EPS | 15.13 | 15.44 | 16.01 | 16.32 | 17.22 | 18.28 | 18.75 | 20.10 | 20.32 | 21.56 | 22.38 | 23.27 | |
| Net margin | 28.32% | 27.51% | 26.75% | 27.22% | 27.08% | 28.41% | 28.91% | 29.55% | 30.00% | 30.56% | 28.81% | 29.34% | |
| PBT margin | 35.58% | 33.38% | 32.22% | 33.63% | 34.89% | 35.96% | 35.15% | 36.15% | 37.63% | 37.57% | 35.56% | 36.90% | |
| Tax rate | 20.47% | 17.60% | 16.98% | 19.09% | 22.34% | 20.98% | 17.78% | 18.27% | 20.29% | 18.65% | 19.00% | 20.48% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 12 Aug 2026.
CAPLIPOINT at a glance
- CAPLIPOINT closed at ₹2,679.7 on 6 Oct 2026, +2.91% on the day, +31.6% over one year, 10.4% below its 52-week high of ₹2,990.
- Delivery was 41.7% of traded quantity on 6 Oct 2026, the 41st percentile of its own 1,731 sessions with a reading (20-session average 35.5%, 1-year average 46.0%).
- Market capitalisation is ₹20,369 crore at a trailing P/E of 30.0 (trailing EPS ₹89.2).
- Q1 FY27 results (consolidated, filed 12 Aug 2026): revenue ₹610 crore (+19.6% year on year), net profit ₹179 crore (+18.8%); the price moved +1.1% on the first session after.
- Promoters held 70.57% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 3 Nov 2026 and 13 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE475E01026
SeriesEQ
Listed23 Jun 2014
History from23 Jun 2014
Sessions3,037
Turnover rank#456
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE